Michel M, Zwahlen R, Brand B
Office Fédéral de la Santé Publique, Berne, Suisse.
Ann Med Interne (Paris). 1997;148(4):311-4.
Despite the progress made in screening for blood-transmitted diseases, both the post-infection diagnostic window and the appearance of novel infective agents remain critical issues for the safety of blood transfusions. Viral inactivation methodologies for fresh-frozen-plasma (e.g., treatment with methylene blue or solvent-detergent) are currently being compared, in terms of their activities on viral subtypes and coagulation factors, as well as general toxicity and clinical effects, in order to define the advantages, residual risks and the uncertainties involved in their use.
尽管在血液传播疾病筛查方面取得了进展，但感染后诊断窗口期和新型感染因子的出现仍然是输血安全的关键问题。目前正在比较新鲜冰冻血浆的病毒灭活方法（例如，用亚甲蓝或溶剂去污剂处理），根据它们对病毒亚型和凝血因子的作用、一般毒性和临床效果，以确定其使用的优势、残余风险和不确定性。
